Ocugen, Inc.
OCGN · NASDAQ
Company research
Ocugen, Inc. (NASDAQ: OCGN) is a clinical-stage biopharmaceutical company headquartered in Malvern, Pennsylvania, focused on discovering, developing, and commercializing novel gene and cell therapies to treat blindness-causing diseases. The company's proprietary modifier gene therapy platform takes a gene-agnostic approach, designed to address complex retinal diseases — including retinitis pigmentosa, Stargardt disease, Leber congenital amaurosis, and geographic atrophy (late-stage dry age-related macular degeneration) — across diverse genetic mutations with a single therapeutic candidate. Its lead pipeline assets include OCU400 and OCU410, both investigational gene therapies targeting inherited retinal diseases and dry AMD respectively, as well as OCU200, a novel fusion protein in preclinical evaluation for diabetic macular edema and wet AMD. Founded in 2013 and led by CEO Shankar Musunuri, Ocugen currently has no approved products on the market and operates with approximately 95 full-time employees, maintaining a market capitalization of approximately $508 million.
Research reports
Published on May 29, 2026, Zacks frames Ocugen as a late-stage, catalyst-driven gene therapy company with upside tied to OCU400, OCU410ST and OCU410 milestones, but stresses that pre-commercial status, volatile collaboration revenue, and a runway only into late 2026 keep risk high and justify a neutral stance. The report details 2025 financials, Q1 2026 loss and cash burn, outlines conditional runway extension via warrants, and highlights dilution, execution and regulatory outcomes as key factors investors must monitor.
Noble Capital Markets (via Channelchek) · May 6, 2026Ocugen 1Q26 Reported With Senior Convertible Note OfferingNoble Capital Markets’ May 6, 2026 report reiterates an Outperform rating and $12 price target, arguing that the $115 million 6.75% convertible senior note offering, together with existing cash and warrant proceeds, should provide sufficient funding to advance Ocugen’s three lead ocular gene therapies through pivotal trials, BLA filings and initial launches into 2028. The analysis reviews Q1 2026 results, emphasizes that OCU400, OCU410ST and OCU410 programs are on or ahead of schedule, and flags financing structure, potential dilution from note conversion and timely completion of clinical and CMC milestones as key risks.